By Ian Haworth
Pharmaceutical company Merck announced Monday that they and Ridgeback Biotherapeutics were requesting emergency authorization from the U.S. Food and Drug Administration (FDA) for molnupiravir, its experimental antiviral COVID-19 pill.
“Merck has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for molnupiravir, an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization,” Merck announced in a press release.
Click the link below to read the rest of this story.
Click here to get more news from the Bulldog
On the go, but don’t want to miss any Bulldog news? Go to the App Store and downloads apps for Bulldog Reports and The Bulldog Show to your Apple and Android mobile devices. It’s free!